SCHEMBL5742495

SCHEMBL5742495

O=C1CCCC(=O)N1c1ccc2ccccc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
HTR1A P08908 3/20 0.47
SLC6A4 P31645 2/20 0.47
HRH3 Q9Y5N1 7/20 0.46
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
HTR3E A5X5Y0 2/20 0.46
HTR3B O95264 2/20 0.46
CYP1A2 P05177 2/20 0.46
HTR3A P46098 2/20 0.46
HTR3D Q70Z44 2/20 0.46
HTR3C Q8WXA8 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
ADRB1 P08588 1/20 0.46
CYP3A4 P08684 1/20 0.46
HTR2C P28335 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3798927 0.93 RECQL (0.51) USP2KMT2AMEN1GAAHTR1A
SCHEMBL10792966 0.77 KMT2A (0.48) USP2KMT2AMEN1GAAHTR1A
SCHEMBL11548784 0.75 HTR1A (0.51) USP2KMT2AMEN1GAAHTR1A
SCHEMBL30046397 0.75 HTR1A (0.51) USP2KMT2AMEN1GAAHTR1A
SCHEMBL27662070 0.74 HPGD (0.53) USP2KMT2AMEN1GAAHTR1A
SCHEMBL10609190 0.72 HRH3 (0.63) USP2HTR1ASLC6A4HRH3ALDH1A1
SCHEMBL21047742 0.71 KMT2A (0.53) USP2KMT2AHTR1ASLC6A4HRH3
SCHEMBL30824499 0.71 HRH3 (0.71) USP2HTR1ASLC6A4HRH3ALDH1A1
SCHEMBL5664122 0.71 HRH3 (0.71) USP2HTR1ASLC6A4HRH3ALDH1A1
SCHEMBL29604668 0.71 HRH3 (0.71) USP2HTR1ASLC6A4HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477486-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2004-11-17 EP claimed
EP-4228624-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 Therapeutics, Inc. (US) 2023-08-23 EP disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
EP-1004580-B1 Imides as inhibitors of TNF alpha CELGENE CORP (US) 2006-12-20 EP disclosed
EP-1477486-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2004-11-17 EP disclosed
EP-1004581-A2 Process for the preparation of thalidomide CELGENE CORPORATION (US) 2000-05-31 EP disclosed
EP-1004572-A2 Amines as inhibitors of TNF alpha CELGENE CORPORATION (US) 2000-05-31 EP disclosed
EP-1004580-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2000-05-31 EP disclosed
US-5463063-A Preparation of thalidomide; inhibitor of tumor necrosis factor CELGENE CORPORATION (US) 1995-10-31 US disclosed